• darkblurbg

    Developing precision therapies

    for type 1 diabetes

  • darkblurbg

    Intralymphatic immunotherapy

    with Diamyd®

Available positions at Diamyd Medical

We welcome candidates with relevant experience to join our entrepreneurial and collaborative team.



 Dates for financial information and other events
Data pager
Data pager
December 1, 2022
Annual General Meeting
Annual General Meeting 2021/2022
January 9 − January 12, 2023
BIO Partnering at JPM
January 9-12, 2023, San Francisco, CA
January 25, 2023
Quarterly Report I
Quarterly Report 1 2022/2023
February 27 − March 1, 2023
6th Antigen-Specific Immune Tolerance Summit
April 5, 2023
Quarterly Report II
Quarterly Report 2 2022/2023
June 28, 2023
Quarterly Report III
Quarterly Report 3 2022/2023

We are on the verge of radically changing how autoimmune diabetes should be treated. The antigen-specific immunotherapy Diamyd® targets individuals who carry a specific gene type found in up to 40% of all people who suffer from or are at risk of autoimmune diabetes, a textbook example of precision medicine. This is a great discovery and a paradigm shift in the field.

Ulf Hannelius
President and CEO, Diamyd Medical AB
CEO Comments, Annual Report 21/22


Diamyd Medical develops therapies for type 1 diabetes
The share is listed on Nasdaq First North Growth Market (ticker: DMYD B)

Read More

Order GAD for preclinical research